Summary

Overview
The global compartment syndrome treatment market reached US$ 316.8 million in 2023 and is expected to reach US$ 516.6 million by 2031 growing with a CAGR of 6.3% during the forecast period 2024-2031.
Compartment syndrome is a painful condition that occurs when pressure within the muscles builds to dangerous levels. This pressure can decrease blood flow, which prevents nourishment and oxygen from reaching nerve and muscle cells. Compartment syndrome can be either acute (having severe symptoms for a short period) or chronic (long-lasting).
Acute compartment syndrome is a surgical emergency. There is no effective nonsurgical treatment. An incision and cut open the skin and fascia covering the affected compartment. This procedure is called a fasciotomy.
Chronic compartment syndrome is a nonsurgical treatment. Physical therapy, orthotics (inserts for shoes), and anti-inflammatory medicines may be of limited benefit in relieving symptoms and generally do not allow a return to full activity.
Drugs used for comportment syndrome treatment involve opioids, non-opioids, and NSAIDs. The market is driven by factors such as the increasing incidence of traumatic injuries and technological advancements in treatment.
Market Dynamics: Drivers
Increasing incidence of traumatic injuries
The demand for the global compartment syndrome treatment market is driven by multiple factors. The increasing incidence of traumatic injuries is expected to drive the growth of the market. Traumatic injuries, such as road accidents, sports injuries, and combat injuries, are major causes of compartment syndrome.
Acute compartment syndrome (ACS) most often develops soon after significant trauma, particularly involving long bone fractures. According to Medscape news in January 2023, the frequency of abdominal compartment syndrome in trauma ICU admissions is anywhere from 5 to 15% and 1% of general trauma admissions.
Moreover, major players in the industry's ongoing research studies would propel this market growth. According to an NCBI research publication in March 2024, during the period from 2015 to 2022, a total of 13,305 cases of traumatic compartment syndromes. Of these, 61% manifested in the lower extremities and 11% in the upper extremities. A significant portion of cases lacked precise localization classification (25.2%). Most traumatic compartment syndromes occurred in males (4092 cases in females vs. 9213 in males).
Similarly, as per EFFORT open reviews in December 2023, ACS in tibial fractures varies depending on the injury site, around 12% for tibial plateau fractures, reaching up to 53% in higher-energy patterns.
Restraints
Factors such as the high cost of treatment, the availability of limited treatment options, and limited awareness & diagnosis among individuals, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global compartment syndrome treatment market is segmented based on treatment type, syndrome type, end-users, and region.
The fasciotomy segment accounted for approximately 51.3% of the global compartment syndrome treatment market share
The fasciotomy segment is expected to hold the largest market share over the forecast period. Fascia are the thick sheets of connective tissue that surround muscle compartments. Fasciotomy, a procedure in which the fascia is cut to relieve pressure in the muscle compartment, is used to treat people with acute or chronic compartment syndrome.
A fasciotomy consists of 1 or more fascial incisions and remains the only effective way to treat acute compartment syndrome. Fasciotomy is a surgical procedure that involves making an incision in the skin and underlying tissue to relieve pressure on the affected nerve or muscle. According to Healio news in April 2024, Atraumatic idiopathic compartment syndrome requiring emergent fasciotomy.
Moreover, key players in the market technological advancements in fasciotomy drive the market growth. The development of advanced intracompartmental pressure monitoring devices enhances the accuracy and reliability of diagnosing compartment syndrome, guiding surgeons in determining the necessity and timing of fasciotomy.
As per NCBI publication in March 2024, an FDA-approved device was used for continuous compartment pressure monitoring. The sensor tip is placed in the muscle belly, and the trochar is then detached from the sensor, allowing the sensor to remain in place. Innovations in imaging technologies, such as portable ultrasound devices, aid in pre-operative planning and intraoperative assessment during fasciotomy procedures.
Geographical Analysis
North America accounted for approximately 43.8% of the global compartment syndrome treatment market share.
North America region is expected to hold the largest market share over the forecast period owing to the high incidence of trauma and sports-related injuries as per NCBI April 2024, the incidence of ACS is estimated to be 7.3 per 100,000 in males and 0.7 per 100,000 in females.
According to the National Safety Council in 2023, 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. The activities most frequently associated with injuries are exercise, cycling, and basketball. Amongst American children and adolescents, sports and recreational activities contribute to the growth of the market.
Moreover, key player's innovative initiatives, growing awareness of the syndrome, advancements in medical technology, and increased focus on sports medicine propel this market growth in this region. For instance, in August 2023, Sentinel Medical Technologies addressed the IAP transducer shortage with the trauma ward. IAP monitoring is a critical component of patient care in OR and ICU settings. It serves as a crucial guide for medical teams in assessing the risk of developing Intra-Abdominal Hypertension (IAH) and Abdominal Compartment Syndrome (ACS), conditions that can have severe consequences if not addressed promptly.
Market Segmentation
By Treatment Type
• Fasciotomy
• Orthotics
• Drugs
o Opioids
o Non-Opioids
o NSAIDs
By Syndrome Type
• Acute Compartment Syndrome
• Chronic Compartment Syndrome
By End-User
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the compartment syndrome treatment market include Stryker, BD, C2DX, Inc., Accuryn Medical, Medline Industries, LP., MY01, Convatec Inc., RAUMEDIC AG, Millar, LLC, and Mirador Biomedical among others.
Key Developments
 In May 2021, MY01 Inc. received FDA clearance for the MY01 continuous compartment pressure monitor as an aid in the diagnosis of compartment syndrome.
Why Purchase the Report?
• To visualize the global compartment syndrome treatment market segmentation based on treatment type, syndrome type, end-users, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the compartment syndrome treatment market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global compartment syndrome treatment market report would provide approximately 62 tables, 58 figures, and 181 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Syndrome Type
3.3. Snippet by End-Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Incidence of Traumatic Injuries
4.1.1.2. Technological Advancements in Treatment
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Fasciotomy *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Orthotics
6.4. Drugs
6.4.1. Opioids
6.4.2. Non-Opioids
6.4.3. NSAIDs
7. By Syndrome Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type Market Attractiveness Index, By Syndrome Type
7.2. Acute Compartment Syndrome*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chronic Compartment Syndrome
8. By End-Users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
8.1.2. Market Attractiveness Index, By End-Users
8.2. Hospitals & Clinics *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Syndrome Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-Users
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Stryker *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. BD
11.3. C2DX, Inc
11.4. Accuryn Medical
11.5. Medline Industries, LP.
11.6. MY01
11.7. Convatec Inc
11.8. RAUMEDIC AG
11.9. Millar, LLC
11.10. Mirador Biomedical
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us